Ubs Group Ag Ligand Pharmaceuticals Inc Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Group Ag holds 11,497 shares of LGND stock, worth $1.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,497

Previous 38,786 70.36%

Holding current value

$1.37 Million

Previous $3.27 Million 64.78%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$82.7 - $110.11 $2.26 Million - $3 Million	-27,289 Reduced 70.36%	11,497 $1.15 Million
Q2 2024 Aug 13, 2024	BUY	$68.53 - $87.91 $392,197 - $503,108	5,723 Added 17.31%	38,786 $3.27 Million
Q1 2024 May 13, 2024	BUY	$68.64 - $89.2 $963,431 - $1.25 Million	14,036 Added 73.77%	33,063 $2.42 Million
Q4 2023 Feb 09, 2024	BUY	$49.57 - $72.63 $600,342 - $879,621	12,111 Added 175.12%	19,027 $1.36 Million
Q3 2023 Nov 09, 2023	SELL	$58.86 - $72.67 $68,218 - $84,224	-1,159 Reduced 14.35%	6,916 $414,000
Q2 2023 Aug 11, 2023	BUY	$69.53 - $79.33 $479,339 - $546,901	6,894 Added 583.74%	8,075 $582,000
Q1 2023 May 12, 2023	SELL	$65.67 - $77.08 $31,455 - $36,921	-479 Reduced 28.86%	1,181 $86,000
Q4 2022 Feb 08, 2023	BUY	$61.72 - $96.74 $80,236 - $125,762	1,300 Added 361.11%	1,660 $110,000
Q3 2022 Nov 10, 2022	SELL	$0.01 - $107.56 $3 - $33,343	-310 Reduced 46.27%	360 $31,000
Q2 2022 Aug 10, 2022	SELL	$74.52 - $117.06 $2.28 Million - $3.58 Million	-30,614 Reduced 97.86%	670 $60,000
Q1 2022 May 16, 2022	BUY	$94.99 - $151.56 $419,475 - $669,288	4,416 Added 16.44%	31,284 $3.52 Million
Q4 2021 Feb 14, 2022	SELL	$127.69 - $165.85 $9,449 - $12,272	-74 Reduced 0.27%	26,868 $4.15 Million
Q3 2021 Nov 15, 2021	BUY	$102.33 - $144.73 $1.77 Million - $2.51 Million	17,319 Added 179.98%	26,942 $3.75 Million
Q2 2021 Aug 13, 2021	BUY	$113.03 - $155.64 $663,373 - $913,451	5,869 Added 156.34%	9,623 $1.26 Million
Q1 2021 May 12, 2021	SELL	$99.52 - $215.83 $145,995 - $316,622	-1,467 Reduced 28.1%	3,754 $573,000
Q4 2020 Feb 11, 2021	BUY	$80.55 - $106.05 $31,978 - $42,101	397 Added 8.23%	5,221 $519,000
Q3 2020 Nov 12, 2020	SELL	$89.56 - $126.72 $246,737 - $349,113	-2,755 Reduced 36.35%	4,824 $460,000
Q2 2020 Jul 31, 2020	BUY	$68.28 - $123.65 $221,295 - $400,749	3,241 Added 74.71%	7,579 $848,000
Q1 2020 May 01, 2020	SELL	$63.37 - $107.88 $551,445 - $938,771	-8,702 Reduced 66.73%	4,338 $315,000
Q4 2019 Feb 14, 2020	SELL	$96.94 - $113.59 $3.58 Million - $4.19 Million	-36,912 Reduced 73.89%	13,040 $1.36 Million
Q3 2019 Nov 14, 2019	BUY	$86.25 - $120.16 $3.34 Million - $4.66 Million	38,757 Added 346.2%	49,952 $4.97 Million
Q2 2019 Aug 14, 2019	SELL	$107.38 - $129.34 $2.59 Million - $3.12 Million	-24,157 Reduced 68.33%	11,195 $1.28 Million
Q1 2019 May 14, 2019	SELL	$105.93 - $142.47 $1.17 Million - $1.58 Million	-11,056 Reduced 23.82%	35,352 $4.44 Million
Q4 2018 Feb 14, 2019	BUY	$128.36 - $272.13 $1.02 Million - $2.16 Million	7,921 Added 20.58%	46,408 $6.3 Million
Q3 2018 Nov 14, 2018	BUY	$211.18 - $274.49 $3.99 Million - $5.19 Million	18,899 Added 96.48%	38,487 $10.6 Million
Q2 2018 Aug 14, 2018	SELL	$150.77 - $207.98 $6.42 Million - $8.85 Million	-42,566 Reduced 68.48%	19,588 $4.06 Million
Q1 2018 May 15, 2018	BUY	$138.63 - $182.62 $7.09 Million - $9.34 Million	51,166 Added 465.65%	62,154 $10.3 Million
Q4 2017 Feb 14, 2018	SELL	$128.36 - $147.04 $2.08 Million - $2.38 Million	-16,213 Reduced 59.6%	10,988 $1.51 Million
Q3 2017 Nov 14, 2017	SELL	$120.91 - $137.94 $1.43 Million - $1.63 Million	-11,838 Reduced 30.32%	27,201 $3.7 Million
Q2 2017 Aug 14, 2017	BUY	N/A	20,258 Added 107.86%	39,039 $4.74 Million
Q1 2017 Nov 14, 2017	BUY	N/A	18,781	18,781 $1.99 Million

Others Institutions Holding LGND

# of Institutions

257

Shares Held

18.2M

Call Options Held

26.8K

Put Options Held

9.3K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.01B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account